LRMR - Larimar Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$8.50
DETAILS
HIGH:
$12.00
LOW:
$5.00
MEDIAN:
$8.50
CONSENSUS:
$8.50
UPSIDE:
98.60%
About Larimar Therapeutics, Inc. (https://www.larimartx.com)
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Carole S. Ben-Maimon | Chief Executive Officer, President & Director | 1959 | $976,403 USD |
| Michael Celano | Secretary & Chief Financial Officer | 1959 | $696,996 USD |
| Gopi Shankar | Chief Development Officer | 1971 | $642,351 USD |
| Francis Michael Conway | Vice President & Controller | – | – |
| Jennifer Spokes Johansson | Vice President of Legal & Compliance | – | – |
| John Berman | Vice President of Finance & Administration | – | – |
| Russell G. Clayton | Chief Medical Officer | 1961 | – |